questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Interleukines
Interleukine-27
Interleukine-27 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Interleukine-27
Cytokines
Cytométrie en flux
Tests immunologiques
Maladies auto-immunes
Inflammation
Inflammation
Gravité des maladies
Symptômes
5
Douleurs articulaires
Maladies inflammatoires
Symptômes respiratoires
Maladies pulmonaires
Symptômes neurologiques
Conditions neurologiques
Prévention
5
Modes de vie sains
Gestion du stress
Alimentation
Inflammation
Exercice physique
Santé immunitaire
Traitements
5
Thérapies biologiques
Maladies auto-immunes
Médicaments anti-inflammatoires
Modulation
Efficacité des traitements
Réponse immunitaire
Complications
5
Complications
Maladies auto-immunes
Maladies chroniques
Arthrite
Cancer
Croissance tumorale
Troubles neurologiques
Sclérose en plaques
Facteurs de risque
5
Maladies auto-immunes
Facteurs de risque
Alimentation
Régimes alimentaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Interleukine-27 : Questions médicales les plus fréquentes",
"headline": "Interleukine-27 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Interleukine-27 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Interleukine-27"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Interleukines",
"url": "https://questionsmedicales.fr/mesh/D007378",
"about": {
"@type": "MedicalCondition",
"name": "Interleukines",
"code": {
"@type": "MedicalCode",
"code": "D007378",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.465"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Interleukine-27",
"alternateName": "Interleukin-27",
"code": {
"@type": "MedicalCode",
"code": "D064094",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Cory M Robinson",
"url": "https://questionsmedicales.fr/author/Cory%20M%20Robinson",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States."
}
},
{
"@type": "Person",
"name": "Tomozumi Imamichi",
"url": "https://questionsmedicales.fr/author/Tomozumi%20Imamichi",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA."
}
},
{
"@type": "Person",
"name": "Jessica M Povroznik",
"url": "https://questionsmedicales.fr/author/Jessica%20M%20Povroznik",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States."
}
},
{
"@type": "Person",
"name": "Jordan K Vance",
"url": "https://questionsmedicales.fr/author/Jordan%20K%20Vance",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States."
}
},
{
"@type": "Person",
"name": "Xiaojun Hu",
"url": "https://questionsmedicales.fr/author/Xiaojun%20Hu",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Lipoprotein(a) is a highly atherogenic lipoprotein: pathophysiological basis and clinical implications.",
"datePublished": "2024-08-13",
"url": "https://questionsmedicales.fr/article/39360655",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/HCO.0000000000001170"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a).",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37273067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11883-023-01113-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of lipoprotein(a) with aortic dissection.",
"datePublished": "2022-08-04",
"url": "https://questionsmedicales.fr/article/35925003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/clc.23834"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aspirin and lipoprotein(a) in primary prevention.",
"datePublished": "2023-07-31",
"url": "https://questionsmedicales.fr/article/37527183",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOL.0000000000000891"
}
},
{
"@type": "ScholarlyArticle",
"name": "[State of the art: lipoprotein apheresis].",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36990113",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-1516-2761"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Interleukines",
"item": "https://questionsmedicales.fr/mesh/D007378"
},
{
"@type": "ListItem",
"position": 6,
"name": "Interleukine-27",
"item": "https://questionsmedicales.fr/mesh/D064094"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Interleukine-27 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Interleukine-27",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Interleukine-27",
"description": "Comment mesurer l'IL-27 dans le sang ?\nQuels tests sont utilisés pour évaluer l'IL-27 ?\nL'IL-27 est-elle mesurée dans des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-27 ?\nL'IL-27 peut-elle être un indicateur de gravité ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Interleukine-27",
"description": "Quels symptômes sont liés à une élévation de l'IL-27 ?\nL'IL-27 est-elle liée à des douleurs articulaires ?\nQuels signes cliniques sont associés à l'IL-27 ?\nL'IL-27 influence-t-elle les symptômes respiratoires ?\nY a-t-il des symptômes neurologiques liés à l'IL-27 ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Interleukine-27",
"description": "Peut-on prévenir l'élévation de l'IL-27 ?\nY a-t-il des vaccins liés à l'IL-27 ?\nComment l'alimentation influence-t-elle l'IL-27 ?\nL'exercice physique affecte-t-il l'IL-27 ?\nLe sommeil influence-t-il l'IL-27 ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Interleukine-27",
"description": "Quels traitements ciblent l'IL-27 ?\nL'IL-27 peut-elle être inhibée ?\nQuels médicaments affectent l'IL-27 ?\nL'IL-27 est-elle une cible pour l'immunothérapie ?\nComment l'IL-27 influence-t-elle les traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Interleukine-27",
"description": "Quelles complications sont liées à l'IL-27 ?\nL'IL-27 est-elle impliquée dans des maladies chroniques ?\nComment l'IL-27 affecte-t-elle le cancer ?\nY a-t-il des risques d'infection liés à l'IL-27 ?\nL'IL-27 est-elle liée à des troubles neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Interleukine-27",
"description": "Quels facteurs augmentent l'IL-27 ?\nL'âge influence-t-il les niveaux d'IL-27 ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe tabagisme affecte-t-il l'IL-27 ?\nY a-t-il un lien entre l'IL-27 et l'alimentation ?",
"url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Lipoprotein(a)#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer l'IL-27 dans le sang ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-27 peut être mesurée par des tests ELISA dans des échantillons de sérum."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'IL-27 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques comme l'ELISA et la cytométrie en flux sont utilisés."
}
},
{
"@type": "Question",
"name": "L'IL-27 est-elle mesurée dans des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-27 est souvent mesurée dans des maladies auto-immunes et inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont associés à l'IL-27 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-27 est souvent associée à d'autres cytokines comme l'IL-6 et l'IL-10."
}
},
{
"@type": "Question",
"name": "L'IL-27 peut-elle être un indicateur de gravité ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés d'IL-27 peuvent indiquer une inflammation sévère."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une élévation de l'IL-27 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une élévation de l'IL-27 peut entraîner des symptômes d'inflammation comme la fièvre."
}
},
{
"@type": "Question",
"name": "L'IL-27 est-elle liée à des douleurs articulaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-27 peut contribuer à des douleurs articulaires dans les maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à l'IL-27 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes cliniques incluent fatigue, douleurs et symptômes systémiques d'inflammation."
}
},
{
"@type": "Question",
"name": "L'IL-27 influence-t-elle les symptômes respiratoires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-27 peut exacerber les symptômes respiratoires dans certaines maladies pulmonaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à l'IL-27 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés d'IL-27 peuvent être associés à des symptômes neurologiques dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'élévation de l'IL-27 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modes de vie sains et une gestion du stress peuvent aider à prévenir l'élévation de l'IL-27."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins liés à l'IL-27 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant l'IL-27."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'IL-27 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation anti-inflammatoire peut aider à réguler les niveaux d'IL-27."
}
},
{
"@type": "Question",
"name": "L'exercice physique affecte-t-il l'IL-27 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire les niveaux d'IL-27 et améliorer la santé immunitaire."
}
},
{
"@type": "Question",
"name": "Le sommeil influence-t-il l'IL-27 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil adéquat est crucial pour maintenir des niveaux sains d'IL-27 et une bonne santé."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'IL-27 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies biologiques ciblant l'IL-27 sont en développement pour les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'IL-27 peut-elle être inhibée ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des inhibiteurs spécifiques de l'IL-27 sont à l'étude pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent l'IL-27 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments anti-inflammatoires peuvent moduler les niveaux d'IL-27."
}
},
{
"@type": "Question",
"name": "L'IL-27 est-elle une cible pour l'immunothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-27 est une cible potentielle pour l'immunothérapie dans le cancer."
}
},
{
"@type": "Question",
"name": "Comment l'IL-27 influence-t-elle les traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-27 peut influencer l'efficacité des traitements en modulant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à l'IL-27 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés d'IL-27 peuvent entraîner des complications dans les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'IL-27 est-elle impliquée dans des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-27 est associée à des maladies chroniques comme l'arthrite et le lupus."
}
},
{
"@type": "Question",
"name": "Comment l'IL-27 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-27 peut avoir un rôle double dans le cancer, favorisant ou inhibant la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'infection liés à l'IL-27 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés d'IL-27 peuvent augmenter le risque d'infections en modulant l'immunité."
}
},
{
"@type": "Question",
"name": "L'IL-27 est-elle liée à des troubles neurologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux d'IL-27 peuvent être associés à des troubles neurologiques comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent l'IL-27 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, l'obésité et les infections chroniques peuvent augmenter les niveaux d'IL-27."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'IL-27 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'IL-27 peuvent augmenter avec l'âge, affectant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de maladies auto-immunes présentent souvent des niveaux élevés d'IL-27."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il l'IL-27 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter les niveaux d'IL-27 et aggraver l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'IL-27 et l'alimentation ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent influencer les niveaux d'IL-27, notamment les régimes riches en sucres."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States.
Vaccine Development Center, West Virginia University Health Sciences Center, Morgantown, WV, United States.
Publications dans "Interleukine-27" :
4 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States.
Vaccine Development Center, West Virginia University Health Sciences Center, Morgantown, WV, United States.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, USA.
Publications dans "Interleukine-27" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Haematology and Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
National Centre for Cell Science, Pune, India.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
National Centre for Cell Science, Pune, India.
Trident Academy of Creative Technology, Bhubaneswar, India.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Department of Neurology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China.
Publications dans "Interleukine-27" :
2 publications dans cette catégorie
Affiliations :
Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Publications dans "Interleukine-27" :
Lipoprotein(a) has been identified as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. However, as reviewed here, there is ongoing debate as to the ke...
Genetic analyses have revealed that Lp(a) on a per-particle basis is markedly (about six-fold) more atherogenic than LDL. Oxidized phospholipids carried on Lp(a) have been found to have substantial pr...
Lp(a) is a highly atherogenic lipoprotein and a viable target for intervention in a significant proportion of the general population. Better understanding the basis of its enhanced atherogenicity is i...
Familial hypercholesterolemia (FH) and hyperlipoproteinemia(a) are relatively common disorders, posing a significant health burden due to increased risk of atherosclerotic cardiovascular disease (ASCV...
Availability and indications for lipoprotein apheresis vary across the globe. On average, greater than 60% of atherogenic apoB-containing lipoproteins are immediately reduced following a single proced...
Lipoprotein(a) [Lp(a)] is associated with coronary atherosclerotic heart disease, aortic stenosis, stroke, and heart failure. We aimed to determine the relationship between Lp(a) and aortic dissection...
Two hundred patients with AD were included in our case group. The control group consisted of 200 non-AD people who were age- (±5 years) and gender-matched to the case group. Data were collected retros...
Patients with AD had greater median Lp(a) concentrations than non-AD people (152.50 vs. 81.75 mg/L). Lp(a) was associated with AD in a multivariate logistic regression analysis (odds ratio, 8.03; 95% ...
High levels of Lp(a) are strongly associated with AD, independent of other cardiovascular risk factors....
Lipoprotein(a) [Lp(a)] is causally associated with cardiovascular diseases, and elevated levels are highly prevalent. However, there is a lack of available therapies to address Lp(a)-mediated risk. Th...
Aspirin has been demonstrated to have a clear benefit in secondary prevention of cardiovascular disease, but recent primary prevention trials have at best demonstrated a small benefit. However, indivi...
Individuals with elevated Lp(a) may benefit from aspirin therapy in primary prevention, but further study with plasma Lp(a) levels, broader populations, and randomization of aspirin are needed....
Lipoprotein apheresis (LA) is usually a last resort in cardiovascular high-risk patients in the context of secondary prevention after lifestyle measures and maximal pharmacotherapy have failed to prev...
It is well established that lipoprotein(a)[Lp(a)] and low-density lipoprotein cholesterol (LDL-C) play a vital role in atherosclerosis. We investigated the prevalence and prognostic implications of in...
A total of 9,190 patients with CAD after PCI were consecutively enrolled in the study and subsequently divided into three groups according to baseline LDL-C at cut-off of 70 and 100 mg/dl. Increased L...
During an average of 5.0 y of follow-up, 354 (3.9 %) patients experienced all-cause death with 213(2.3 %) of whom from cardiac death. Increased Lp(a) was present in 25.7 %, 34.2 %, and 40.6 % across t...
We confirmed that increased Lp(a) was associated with increased risk of long-term outcomes, and such an association was modified by the baseline LDL-C concentrations. Screening of high Lp(a) in indivi...
To review evidence of existing and new pharmacological therapies for lowering lipoprotein(a) (Lp[a]) concentrations and their impact on clinically relevant outcomes....
We searched for literature pertaining to Lp(a) and pharmacological treatments in PubMed. We reviewed articles published between 1963 and 2020....
We found that statins significantly increased Lp(a) concentrations. Therapies that demonstrated varying degrees of Lp(a) reduction included ezetimibe, niacin, proprotein convertase subtilisin/kexin ty...
There are multiple lipid-lowering agents currently being used to treat hyperlipidemia that also have a Lp(a)-lowering effect. Two RNA therapies specifically targeted to lower Lp(a) are being investiga...
There is abundant evidence that elevated lipoprotein(a) [LP(a)] associates with cardiovascular risk. Most lipid modifying therapies don't reduce Lp(a), but new technologies are emerging that act upstr...
Despite the benefit of therapies for the prevention of atherosclerotic cardiovascular disease (ASCVD), Lp(a) is one of the 'residual risks,' established by observational and Mendelian randomization st...
New Lp(a) lowering therapies have the potential to contribute to the personalized prevention of ASCVD....
Plasma low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are both associated with coronary heart disease (CHD). This study investigated whether elevated plasma Lp(a) concentration...
Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) (n = 4,585) were categorized into four groups: Group 1: LDL-C ≤ 100 mg/dL, Lp(a) < 50 mg/dL; Group 2: LDL-C > 100 mg/dL, Lp(a) < 50 m...
Participants were followed for a mean of 13.4 years and a total of 315 CHD events occurred. Compared to participants with LDL-C ≤ 100 mg/dL and Lp(a) < 50 mg/dL, those with LDL-C > 100 mg/dL and Lp(a)...
When Lp(a) was elevated, risk of CHD events increased, regardless of baseline LDL-C....
Approximately 5 % of the population have highly elevated levels of lipoprotein(a) (Lp(a)), which is a genetically determined risk factor for cardiovascular disease. Measuring lipoprotein(a) can improv...